select trial semaglutide cardiovascular outcomes non-diabetic 2023 and in patients with obesity and prevalent heart failure: a prespecified analysis of the U.S. Eligibility and Preventable Cardiovascular,

Most patients notice appetite suppression within the first 1 to 2 weeks and measurable weight loss within 4 to 8 weeks

FDA approval is for BMI 30+ (or 27+ with weight-related conditions)

Journal of Obesity & Metabolic Syndrome , 31(2), 73-83

It is not recommended to stop taking Ozempic without professional advice and monitoring

Ozempic: Approved by the FDA on June 4, 2021, for chronic weight management in patients with obesity (body mass index of 30 or more) and overweight (body mass index of 27 or more) with a weight-related condition like cardiovascular disease, high blood pressure, or type 2 diabetes

Always follow guidance and professional advice when using these treatments